<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02880735</url>
  </required_header>
  <id_info>
    <org_study_id>C46-15</org_study_id>
    <nct_id>NCT02880735</nct_id>
  </id_info>
  <brief_title>Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy</brief_title>
  <official_title>Effect of Noninvasive Mechanical Ventilation on Ventilatory Response in Patients With Myotonic Dystrophy Type 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Respiratory Diseases, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Respiratory Diseases, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been suggested that patients with Myotonic Dystrophy type 1 have primary altered
      ventilatory response to chemical stimuli and chronic hypoventilation is related not always to
      muscle weakness. Also, it is known that Non Invasive Mechanical Ventilation can improve
      ventilatory response to chemical stimuli, especially to hypercapnia.

      This study evaluates the effect of Non Invasive Mechanical Ventilation on ventilatory
      response in patients with Type 1 Myotonic Dystrophy, the ventilatory response to chemical
      stimuli will be measured before and after mechanical ventilation in patients with myotonic
      dystrophy type 1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 1 Myotonic Dystrophy is a hereditary neuromuscular disease with an autosomal dominant
      pattern whose prevalence is 1/8000 inhabitants and is the most common muscular dystrophy in
      adults. It is multisystem disease and is characterized by myotonia, progressive muscle loss
      and a wide spectrum of manifestations.

      Myotonic dystrophy type 1 causes a high impact on health and quality of life of patients as
      functional impairment can reach the incapacity and total dependence in basic activities of
      daily living. As in most neuromuscular diseases, progressive muscle weakness at some point in
      the evolution affects the respiratory muscles. However, in some patients with myotonic
      dystrophy type 1 it has been observed that muscle weakness does not explain ventilatory
      failure, and is believed to be due to a primary reduction in the central ventilatory response
      to hypercapnia present in this disease.

      Non Invasive Mechanical Ventilation (NIV) is a long-term treatment that provides ventilatory
      assistance through an interface that does not invade the airway and currently can be provided
      to patients in the home environment; It is a resource that has shown to improve the quality
      of life, daytime gas exchange and survival in patients with neuromuscular diseases, even when
      used only during sleep. It is not clear the mechanism by which NIV during daytime sleep
      improves gas exchange in patients with neuromuscular diseases, even in advanced stages where
      breathing muscles effectors are severely affected.

      It has been proposed that NIV used during sleep can improve the sensitivity of the
      respiratory center to carbon dioxide but this has not been demonstrated in patients with Type
      1 Myotonic Dystrophy, to answer this question, it is proposed to compare the central
      ventilatory response to chemical stimuli after a period of NIV in patients with Type 1
      Myotonic Dystrophy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilatory Response to Chemical Stimuli</measure>
    <time_frame>Three months</time_frame>
    <description>Increase the minute volume per unit of hypercapnia or hypoxemia, in a test of acute stimulation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life Measured by Short Form 36 (SF-36)</measure>
    <time_frame>Three months</time_frame>
    <description>Scale for measuring the quality of life related to health in 8 domains (vitality, physical functioning, bodily pain, general health perception, physical role functioning, emotional role functioning, social role functioning, mental health), each rated from 0 to 100%. The higher score means better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnoea evaluated by the modified scale of the Medical Research Council (mMRC)</measure>
    <time_frame>Three months</time_frame>
    <description>Rate dyspnea at 5 degrees from 0 to 5. 0: Not troubled by breathless except on strenuous exercise. 1: Short of breath when hurrying on a level or when walking up a slight hill. 2: Walks slower than most people on the level, stops after a mile or so, or stops after 15 minutes walking at own pace. 3: Stops for breath after walking 100 yards, or after a few minutes on level ground. 4: Too breathless to leave the house, or breathless when dressing/undressing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality assessed by The Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>three months</time_frame>
    <description>Assesses sleep quality. Contains 19 questions, each weighted on a 0-3 interval scale. A global PSQI score is taken from the survey, with lower scores correlating to better sleep quality.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Myotonic Dystrophy 1</condition>
  <condition>Steinert Disease</condition>
  <arm_group>
    <arm_group_label>Non Invasive Ventilation.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It will provide noninvasive mechanical ventilation with the following specifications:
Bilevel devices: Pressurized bilevel mode Spontaneous/Time. Interface: Facial mask Usage: During sleep Frequency: Daily Duration: Three months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non Invasive Ventilation.</intervention_name>
    <description>Non Invasive Mechanical Ventilation through oronasal mask. Mode: Bilevel with rate backup (spontaneous/time). Inspiratory Pressure: 30-10, Expiratory Pressure : 4-15, Backup Rate;14-25 rpm. Use Time: During Sleep.</description>
    <arm_group_label>Non Invasive Ventilation.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Classic variety of Myotonic Dystrophy Type 1

          -  Molecular confirmation through the standard method

        Exclusion Criteria:

          -  Using currently invasive mechanical ventilation.

          -  Acute decompensation of respiratory or cardiac origin in the last 6 months, which
             required hospital care.

          -  Drugs that may alter the ventilatory response: benzodiazepines, neuroleptics,
             corticosteroids, theophylline, acetazolamide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rogelio Perez Padilla, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Respiratory Diseases, Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martha G Torres Fraga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Respiratory Diseases, Mexico</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martha G Torres Fraga, MD</last_name>
    <phone>(52) 5556668640</phone>
    <email>dra_marthagtf@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jose L Carrillo Alduenda, MD</last_name>
    <phone>(52)5554871700</phone>
    <phone_ext>5242</phone_ext>
    <email>jlcarrillo14@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institute Of Respiratory Diseases</name>
      <address>
        <city>Mexico</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha G Torres Fraga, MD</last_name>
      <phone>(52)5556668640</phone>
      <email>dra_marthagtf@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Martha G Torres Fraga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose L Carrillo Alduenda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Torre Bouscoulet, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oscar Hernandez Hernandez, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Meola G. Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies. Acta Myol. 2013 Dec;32(3):154-65. Review.</citation>
    <PMID>24803843</PMID>
  </results_reference>
  <results_reference>
    <citation>Mankodi A, Thornton CA. Myotonic syndromes. Curr Opin Neurol. 2002 Oct;15(5):545-52. Review.</citation>
    <PMID>12351998</PMID>
  </results_reference>
  <results_reference>
    <citation>Carroll JE, Zwillich CW, Weil JV. Ventilatory response in myotonic dystrophy. Neurology. 1977 Dec;27(12):1125-8.</citation>
    <PMID>563010</PMID>
  </results_reference>
  <results_reference>
    <citation>Poussel M, Thil C, Kaminsky P, Mercy M, Gomez E, Chaouat A, Chabot F, Chenuel B. Lack of correlation between the ventilatory response to CO2 and lung function impairment in myotonic dystrophy patients: evidence for a dysregulation at central level. Neuromuscul Disord. 2015 May;25(5):403-8. doi: 10.1016/j.nmd.2015.02.006. Epub 2015 Feb 17.</citation>
    <PMID>25753091</PMID>
  </results_reference>
  <results_reference>
    <citation>Jammes Y, Pouget J, Grimaud C, Serratrice G. Pulmonary function and electromyographic study of respiratory muscles in myotonic dystrophy. Muscle Nerve. 1985 Sep;8(7):586-94.</citation>
    <PMID>4047090</PMID>
  </results_reference>
  <results_reference>
    <citation>Brooks D, De Rosie J, Mousseau M, Avenda√±o M, Goldstein RS. Long term follow-up of ventilated patients with thoracic restrictive or neuromuscular disease. Can Respir J. 2002 Mar-Apr;9(2):99-106.</citation>
    <PMID>11972163</PMID>
  </results_reference>
  <results_reference>
    <citation>Annane D, Quera-Salva MA, Lofaso F, Vercken JB, Lesieur O, Fromageot C, Clair B, Gajdos P, Raphael JC. Mechanisms underlying effects of nocturnal ventilation on daytime blood gases in neuromuscular diseases. Eur Respir J. 1999 Jan;13(1):157-62.</citation>
    <PMID>10836341</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myotonic Dystrophy</keyword>
  <keyword>Noninvasive Ventilation</keyword>
  <keyword>Respiratory Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Participant data to be shared will be: Results of functional testing and prescription ventilation.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

